[CIS PIDD] [cis-pidd] IVIG dosing based on ideal body weight

[Ravishankar.Sargur at sth.nhs.uk]

Dear Chris,

The UK IVIG demand management guidelines had looked at this.  See pages 13-15 of http://www.ivig.nhs.uk/documents/dh_129666.pdf .

The recommendation is for patients with BMI > 30 kg/m2 or if actual weight >20% more than IBW, prescribers should consider using adjusted-bodyweight
dosing of immunoglobulin.

BW

Ravi

Dr Ravishankar Sargur
MD, FRCPath, FRCP
Consultant Clinical Immunologist
Immunology, NGH
Sheffield Teaching Hospitals Foundation NHS Trust.
Herries Road
Sheffield
S5 7AU
UK

Phone - 0044 114 27 15704
Fax - 0044 114 22 69244


Honorary Senior Lecturer
Dept of Infection and Immunity
University of Sheffield

Training Programme Director
Immunology
East Midlands Deanery and Yorkshire & Humber Deanery

________________________________
From: Christine M. Seroogy, MD [mailto:cmseroogy at pediatrics.wisc.edu]
Sent: 30 July 2013 23:25
To: CIS-PIDD
Subject: [cis-pidd] IVIG dosing based on ideal body weight

Dear colleagues,

I am interested in hearing how many of you dose IVIG for adults based on ideal body weight (IBW)?  Given that gamma globulin is a precious resource and a significant portion of most pharmacy budgets, our pharmacists have approached me about this strategy.  I couldn't find substantive medical evidence using this dosing regimen for immune deficient patients. I imagine the approach is individualized using clinical correlates, but am interested in hearing the group's thoughts on how many have initiated therapy based on IBW or transitioned to IBW for their patients. And if so, was this effective?

Thank you

Chris


Christine M. Seroogy MD,  FAAAAI
Associate Professor
University of Wisconsin
Department of Pediatrics
Division of Allergy, Immunology & Rheumatology
1111 Highland Avenue
4139 WIMR
Madison, WI  53705-2275
phone: 608-263-2652
fax: 608-265-9721





Confidentiality Notice: The information in this message (and the documents attached to it, if any) is confidential and may be legally privileged. It is intended solely for the addressee. Access to this message by anyone else is unauthorized. If you are not the intended recipient, any disclosure, copying, distribution or any action taken, or omitted to be taken in reliance on it is prohibited and may be unlawful. If you have received this message in error, please delete all electronic copies of this message (and the documents attached to it, if any), destroy any hard copies you may have created and notify me immediately by replying to this email. Thank you.

---

The CIS-PIDD listserv is supported by:

[http://www.clinimmsoc.org/UserFiles/image/cis-pidd-list-logo_v1.jpg]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: ravishankar.sargur at sth.nhs.uk<mailto:ravishankar.sargur at sth.nhs.uk>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824745.d44abf085b2893cde48f010bd9ad8489&n=T&l=cis-pidd&o=43649179

---
The CIS-PIDD listserv is supported by the Clinical Immunology Society
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org to join!

You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183939985.3ea13d40a15475ac00ebbd9cd8a37d6d&n=T&l=cis-pidd&o=43650950
or send a blank email to leave-43650950-183939985.3ea13d40a15475ac00ebbd9cd8a37d6d at lists.clinimmsoc.org
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://seven.pairlist.net/pipermail/pagid/attachments/20130731/bec1fc08/attachment.html>